Thursday, June 13, 2019 1:06:10 PM
Investment Highlights
•
A rare disease focused clinical stage biopharmaceutical company with a pipeline of novel product candidates that are intended
to address unmet need in a variety of metabolic diseases
•
ZGN 1061 for type 2 diabetes with concomitant obesity and/or NASH
•
Diabetes market evolving towards therapies with enhanced A1C lowering efficacy and positive effects on common co morbidities (ob esity/NAFLD)
•
Phase 2 proof of concept trial demonstrated significant A1C lowering efficacy and weight loss, with a safety and tolerability pr ofile generally
comparable to placebo
•
Nonclinical ZGN 1061 studies have demonstrated significant NASH model efficacy, and complementary efficacy in combination with a GLP 1
•
Next milestone: Update on development plans by end of 3Q 2019
•
ZGN 1258 for rare metabolic diseases, including Prader Willi syndrome
•
Prader Willi syndrome is a rare, lethal disease emerging in childhood, with ~200,000 afflicted worldwide; no current therapeutic options available
•
Development plans suspended due to unexpected finding in long term toxicology studies
•
ZGN 1345 for metabolic liver disease
•
Multiple metabolic related liver diseases exist with high unmet medical need, from NAFLD/NASH to hepatocellular carcinoma
•
Compound is an orally dosed MetAP2i with high liver concentrations but minimal to no detectable systemic exposure; once daily do sing expected
•
Named as development candidate 4Q 2018; nonclinical development work underway
•
March 31, 2019 cash position of $105M; runway expected to extend through at least 2020
ZGN
1061 Next Steps
•
Reviewing comprehensive data sets with diabetes/NASH KOLs and potential partners
•
Important progress made toward addressing the FDA Clinical Hold:
•
Received FDA Type A meeting minutes to previously announced clinical hold
•
FDA acknowledged newly developed in vitro assays of human plasma coagulation and tissue factor expression qualitatively
differentiate ZGN 1061
•
Working with FDA to translate in vitro data and confirm relevant safety margins in an in vivo model
•
Exploring a second IND in a population with higher unmet medical need
•
Company expects to provide an update on development plans by end of 3Q 2019
•
Submitting abstracts to present full results of the Phase 2 clinical trial at upcoming medical meetings in 2019
ZGN
1258 Summary
•
Unexpected finding observed in long term toxicology studies
•
Degeneration and other anomalies in muscle tissue from 4 and 6 month rodent studies
•
Observed in different degrees in both vehicle and all dose arms; finding more pronounced at higher doses
•
Finding never observed previously, specific to ZGN 1258
•
Not seen in prior ZGN 1258 rodent studies
•
Not seen in any other species with ZGN 1258
•
Not seen in any other Zafgen MetAP2i program in any long term toxicology study
•
Plan to file an IND suspended while finding is investigated
•
Company will provide an update at a later time, if warranted, following further evaluation
PWS Commitment Continues
•
PATH for PWS natural history study collaboration continues
•
Study being conducted in collaboration with the Foundation for
Prader Willi Research (FPWR) and National Organization for Rare
Disorders (NORD)
•
PATH for PWS designed as 4 year / 500 participant non interventional
natural history study
•
Enrollment kicked off at FPWR annual conference in October; >400
enrolled as of March 2019
ZGN
1345 Oral, Liver Focused MetAP2 Inhibitor
•
ZGN 1345 advanced to development candidate status in 4Q 2018
•
Orally dosed MetAP2i; expected once daily dosing
•
High concentrations in the liver; minimal to no detectable exposure systemically
•
High MetAP2 levels strongly correlated with more severe outcomes in advanced liver disease
•
Positive early data in multiple nonclinical liver disease models with high unmet medical need; further nonclinical
studies ongoing
Recent LRMR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 06:38:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 11:02:18 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 10:05:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 08:57:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/31/2024 08:56:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:07:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:08:07 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/28/2024 04:15:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 08:08:07 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/09/2024 08:50:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:02:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:09:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:06:02 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/15/2024 01:57:52 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/14/2024 10:08:46 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 01:55:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 11:06:09 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/13/2024 09:46:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 12:03:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:33:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:32:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:31:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:31:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 09:08:38 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 06:51:38 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM